Intra-Cellular Therapies to Present at the 15th Annual Needham Healthcare Conference

NEW YORK, April 04, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 15th Annual Needham Healthcare Conference in New York. The presentation is scheduled for Tuesday, April 12, 2016 at 4:20 p.m. EDT.

The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia and bipolar depression. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.

 

Contact:
Juan Sanchez, M.D.
Vice President
Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc.
Phone:  212-923-3344

Burns McClellan, Inc.
Lisa Burns
Justin Jackson (Media)
[email protected]
212-213-0006

Source: Intra-Cellular Therapies, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• SmartMarket Solutions Announces Its BBB Accreditation with an A+ Rating
• Gerstle Snelson Managing Partners Michael Gerstle and Steve Snelson Recognized in the 2027 Edition of The Best Lawyers in America®
• Orsini to Serve as Specialty Pharmacy Partner for Priovant's LISRAYA™ (brepocitinib)